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Abstract Toll-like receptors (TLRs) are activated by microbial
structures. To investigate the mechanisms of TLR activation,
the 10 human TLRs were expressed as chimeras with the integ-
rin Kv and L5 subunits. Co-expression of the Kv-TLR and L5-
TLR chimeras in 293T cells generated 10 TLR homodimers, but
only TLR4/4 could e¡ectively activate NF-UB. TLR4 monomers
also activated NF-UB but it was enhanced upon homodimeriza-
tion. The TLR homodimers showed di¡erential surface/intra-
cellular expression. In TLR heterodimers, only TLR2/1 and
TLR2/6 were potent in NF-UB activation. NF-UB activation
by TLR2/1, TLR2/6 and the TLR4 monomer, but not
TLR4/4, was completely inhibited by dominant negative
MyD88, suggesting that TLR4 homodimers and monomers
could activate NF-UB through di¡erent mechanisms.
4 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Innate immunity is the ¢rst line of host defense against
microbial invasion and it relies on pattern recognition recep-
tors (PRRs) to distinguish the di¡erent types of pathogens
[1,2]. Toll-like receptors (TLRs) are a family of PRRs that
speci¢cally recognize di¡erent pathogen-associated molecular
patterns (PAMPs) [3^5] and potentially function as adjuvant
receptors that modulate immune responses according to the
type of pathogens [6^8]. The mechanisms by which the di¡er-
ent TLRs are activated remain to be determined.
TLRs are type I receptors that contain a large, leucine-rich
extracellular domain and a Toll/IL-1R homology (TIR) cyto-
plasmic domain [9]. IL-1R is activated through heterodimer-
ization or clustering with a related receptor called IL-1R ac-
cessory protein (IL-1R AcP) [10^12]. TLR2 activation by
certain PAMPs also requires the cooperation of TLR1 or
TLR6 [13^15]. When TLR2 was expressed as CD4-nucleated
dimers, the TLR2/1 and TLR2/6 heterodimers, but not the
TLR2/2 homodimers, were found to activate NF-UB [13]. In
fact, TLR2 can also form constitutive heterodimers with
TLR1 or TLR6 upon over-expression that activate NF-UB
independent of PAMP stimulation [13]. CD4-nucleated
TLR4 homodimers also e¡ectively activate NF-UB [13,16,
17]. These studies suggested that dimerization may be a com-
mon mechanism of TLR activation.
To examine whether other TLRs are also activated through
dimerization, we expressed the transmembrane/cytoplasmic
(TM/Cyt) domains of all 10 TLRs as chimeras with the extra-
cellular domains of the integrin Kv and L5 subunits. Co-ex-
pression of the Kv-TLR and L5-TLR chimeras generated all
possible TLR dimers. NF-UB activation by these TLR dimers
was examined.
2. Materials and methods
2.1. Reagents and cell culture
The 293T human embryonic kidney cells were cultured at 37‡C in
the presence of 5% CO2, in DMEM supplemented with 10% bovine
calf serum (HyClone), 100 units/ml penicillin, 100 Wg/ml streptomycin,
2 mM L-glutamine, 1 mM sodium pyruvate, and 0.0012% 2-mecap-
tolethanol. The human monocytic THP-1 cells were cultured in
RPMI1640 with the same supplements and were activated for 24 h
with lipopolysaccharide (LPS) derived from Escherichia coli O55:B5
(Sigma Chemical, St. Louis, MO, USA; 100 ng/ml). RNA was iso-
lated from activated THP-1 cells using the Trizol reagent (Life Tech-
nologies). Anti-His6 (clone BMG-His-1) and anti-c-myc (clone 9E10)
were purchased from Roche Molecular Biochemicals. Anti-human
integrin L5 (clone B5-IVF2) was obtained from Upstate Biotechnol-
ogy (Lake Placid, NY, USA). Anti-human integrin Kv (clone P3G8)
and KvL5 heterodimer (clone P1F6) were purchased from Chemicon
International (Harrow, UK).
2.2. Expression vectors
cDNA encoding the extracellular domains of the integrin Kv and L5
subunits were each cloned into the pcDNA3.1 vector. The Kv cDNA
was ampli¢ed by RT-PCR in three fragments using the following
primer pairs (5P-3P) designed based on the published Kv sequence
[18], i.e. tcccggcttggcgtccc/ctatatctgtggctcctttcattg, acgcagtcccatctcaaa-
tcctt/catcttcttcagtctcagggttc and gctcaaatctatttgacaaagtaag/ttgttcgaa-
cacaggcatgggcgctggct. The three PCR fragments were digested with
HindIII, HindIII/XhoI, and XhoI/SfuI, respectively, and simultaneous-
ly cloned into the EcoRV/SfuI site of the pcDNA3.1 vector in frame
at the 3P end with sequences encoding the c-myc and His6 tags (pKv/
MH). A stop codon was introduced between the myc- the His-coding
sequences, using the QuikChange site-directed mutagenesis kit (Stra-
tagene, La Jolla, CA, USA), to generate the pKv/myc vector. cDNA
for the extracellular domain of L5 was ampli¢ed using the follow-
ing primer pair (5P-3P) [19], i.e. tggtggaattcccgcggagtgcagcga/tttttgttc-
gaagttgggggtgtttccaca, and cloned into the EcoRI/SfuI site of the
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pcDNA3.1 vector (pL5/MH). Sequences encoding the TM/Cyt do-
mains of TLRs were ampli¢ed by PCR from the THP-1 cDNA using
the following primer pairs (5P-3P) : TLR1, cccttcgaaaacataactctgctgat-
cgtc/cgggtttaaacgactatttctttgcttgctctg; TLR2, cccttcgaaacagcactggtgtc-
tggc/cgggtttaaacaacctaggactttatcgacg; TLR3, cccttcgaagaactctttttcatg-
atcaatac/cgggtttaaacaatttaatgtacagagtttttgga; TLR4, cccttcgaaaagacc-
atcattggtgtgtc/cgggtttaaactcttca- gatagatgttgcttc; TLR5, cccttcgaaaag-
ttctcccttttcattgtat/cgggtttaaacgattaggagatggttgctac; TLR6, cccttcgaaa-
acataactctgctgatcgtc/cgggtttaaacttaagatttcacatcattgttttc; TLR7, cccttc-
gaagatctgactaacctgattctg/cgggtttaaacgaagggctagaccgtttcc; TLR8, ccct-
tcgaagatgtcactgcagtgatattat/cgggtttaaacaacgtcagttagtattgcttaat; TLR-
9, cccttcgaagactgtttcgccctctcg/cgggtttaaactccggctcacggctattc; TLR10,
cccttcgaaaacacagctctgttgattgt/cgggtttaaacggactgtgggattttataga.
All PCR products were each cloned into the SfuI/PmeI site of the
pKv/myc and pL5/MH vectors, in place of the myc/His-coding region,
to produce the pKvTLR and pL5TLR expression vectors (Fig. 1A).
cDNA encoding the dominant negative MyD88(152^292) was ampli-
¢ed by RT-PCR from the THP-1 cDNA with the following primer
pair (5P-3P), i.e. gtggaattccaccatggaccccctggggcatatg/gaagggcccgggcag-
ggacaaggcctt, and cloned into the EcoRI/ApaI site of the pcDNA3.1
vector (pMyD88DN). The pGFP-TLR4 vector was constructed as
follows. A DNA fragment encoding the signal peptide and the N-
terminal 5 residues of mature human L5 was ampli¢ed from the
pL5/MH plasmid using a primer pair (5P-3P), i.e. tggtggaattcccgcg-
gagtgcagcga/tatgttgagacctgcgagcc. cDNA encoding GFP was ampli-
¢ed from the pEGFP-C1 plasmid (Clontech) using the following prim-
er pair (5P-3P) : gtgagcaagggcgaggag/ttttgttcgaacttgtacagctcgtccatgc.
The two DNA fragments were digested with EcoRI and SfuI, respec-
tively, and simultaneously ligated into the EcoRI/SfuI site of
pL5TLR4 in place of the L5 sequence. All expression vectors were
veri¢ed by DNA sequencing.
2.3. Protein puri¢cation and Western blotting
293T cells were co-transfected with the pKv/myc and pL5/MH plas-
mids and cultured in the VP-SFM serum-free medium (Life Technol-
ogies) for 48 h. The culture medium was then incubated with Ni-
NTA-agarose (Qiagen, Hilden, Germany) overnight at 4‡C and was,
after washing, eluted with imidazole following the manufacturer’s in-
structions except that CaCl2 and MgCl2 were included at 1 mM in all
bu¡ers. The puri¢ed proteins were separated on 7.5% (w/v) SDS^
PAGE gels and, upon electroblotting onto PVDF membranes, de-
tected with speci¢c antibodies. The blots were developed using the
ECL Western blot detection system (Amersham Pharmacia Biotech).
2.4. NF-UB luciferase assay
293T cells were sub-cultured in 24-well tissue culture plates 24 h
before transfection and were co-transfected with the pKvTLR and/or
the pL5TLR plasmids using the GenePORTER 2 reagent and follow-
ing the manufacturer’s instructions (Gene Therapy Systems, La Jolla,
CA, USA). As negative controls, the cells were transfected with the
pcDNA3.1 vector. The p5UNF-UB-luc (Stratagene, La Jolla, CA)
and pRL-CMV (Promega, Madison, WI, USA) luciferase reporter
plasmids were co-transfected in all experiments and the quantity of
plasmids has been speci¢ed in the ¢gure legends. After 48 h, luciferase
expression in the transfected cells was determined using the Dual Lu-
ciferase Assay kit (Promega).
2.5. Flow cytometry
293T cells were transfected with pKvTLR/pL5TLR plasmid pairs to
express TLR homodimers, e.g. pKvTLR1/pL5TLR1. As controls, the
cells were transfected with the pcDNA3.1 vector. The transfected cells
were harvested in 36 h and, after blocking with 20% (v/v) goat serum,
stained with the P1F6 antibody. Cells were washed in FACSwash
(2.5% (v/v) BCS in PBS) and stained with goat anti-mouse IgG
(FITC-conjugated; Sigma). Cells were also stained after permeabliza-
tion for 10 min with 0.1% saponin in FACSwash. The stained cells
were analyzed on FACScalibur using the CellQuest software (Becton
Dickinson Immunocytometry Systems).
2.6. Sequence analysis
Sequences of TLR1^10 cytoplasmic domains and the TIR domain
of MyD88 (residues 152^292) were extracted from the following Gen-
Bank entries: U88540 (TLR1), U88878 (TLR2), U88879 (TLR3),
U88880 (TLR4), AB060695 (TLR5), AB020807 (TLR6), AF245702
(TLR7), AF245703(TLR8), AF245704 (TLR9), AF196673 (TLR10),
and U84408 (MyD88). Similarity between these sequences were com-
pared using the MultAlin software (http://prodes.toulouse.inra.fr/
multalin/multalin.html).
3. Results
3.1. The extracellular domains of the integrin Kv and L5
subunits express as heterodimers
To examine whether TLRs are activated through dimeriza-
tion, we expressed TLRs as chimeras with the extracellular
domains of integrin Kv and L5 which have been reported to
form stable heterodimers [20]. To determine whether KvL5
heterodimers form in our experimental system, L5 was ex-
pressed with both myc and His tags (L5-MH), whereas Kv
was expressed only with the myc tag (Kv-myc) (Fig. 1A).
Upon co-expression in 293T cells, L5-MH was puri¢ed from
the culture media by a⁄nity chromatography on Ni-NTA-
agarose. Two protein bands of approximately 120 and 90
kDa were found reactive with the anti-myc antibody. Western
blotting with anti-Kv and anti-L5 antibodies con¢rmed that
the larger band was Kv and the smaller band was L5 (Fig. 1B).
The anti-His antibody only recognized the L5 band. There-
fore, despite its lack of the His tag, Kv-myc was co-puri¢ed
with L5-MH. Similar amounts of Kv and L5 were detected
with the anti-myc antibody, implying that, as expected, Kv
and L5 most likely formed 1:1 heterodimers.
Table 1
NF-UB activation by TLR dimers
L5-1 L5-2 L5-3 L5-4 L5-5 L5-6 L5-7 L5-8 L5-9 L5-10
Kv-1 3.10 23.10 2.52 39.14 4.79 3.90 3.14 4.55 1.97 1.17
Kv-2 22.41 3.66 1.72 30.97 4.21 28.21 3.21 4.51 1.69 0.69
Kv-3 2.45 2.21 1.90 30.21 2.45 2.21 2.45 2.69 1.66 0.79
Kv-4 19.45 19.07 16.35 31.93 15.83 18.07 15.07 14.69 11.28 13.45
Kv-5 1.97 3.00 2.07 26.21 3.90 2.76 2.66 2.21 1.97 1.35
Kv-6 2.17 20.97 1.34 20.86 2.62 2.76 2.00 2.76 1.31 1.41
Kv-7 1.79 2.31 2.41 42.14 2.07 1.90 3.93 4.07 1.52 1.00
Kv-8 2.97 2.76 2.35 23.72 2.21 2.52 4.28 3.76 3.72 1.86
Kv-9 1.14 1.55 1.48 28.76 1.97 1.76 1.90 4.41 1.04 2.31
Kv-10 1.14 1.45 1.48 31.38 2.72 2.24 2.28 2.93 1.76 0.83
P 2.28 3.97 1.93 21.72 2.90 1.07 2.14 2.66 1.21 1.07
The 10 pKvTLR and 10 pL5TLR plasmids were co-expressed in 293T cells in 100 possible pairs. The pL5TLR plasmids were also each co-ex-
pressed with the pcDNA3.1 vector. The two luciferase reporter plasmids were co-transfected as in Fig. 2A and all plasmids were used at 250
ng/well. NF-UB activation was presented as folds of increases, taking the relative luciferase activity derived from 293T cells transfected with
pcDNA3.1, in place of the TLR expression vectors, as 1. ‘Kv-1’ denotes Kv-TLR1 and ‘L5-1’ denotes L5-TLR1. ‘P’ denotes the pcDNA3.1/
myc-His vector.
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3.2. Di¡erential sub-cellular targeting of KvL5-TLR
homodimers
To express TLR dimers, sequences encoding the TM/Cyt
domains of TLR1^10 were cloned into the pKv/myc and
pL5/MH vectors in frame with 5P Kv- and L5-coding sequences
(Fig. 1A). The resultant pKvTLR and pL5TLR vectors ex-
press Kv-TLR and L5-TLR chimeras and the ability of these
chimeras to form KvL5-mediated dimers were examined. To
express TLRs as KvL5-mediated homodimers, each pKvTLR
vector was co-expressed with a corresponding pL5TLR vector
in 293T cells and KvL5 dimers was detected by £ow cytometry
using the P1F6 antibody. The antibody detected the expres-
sion of chimeric, KvL5-mediated TLR1, TLR6, TLR10 and,
to a lesser extent, TLR2, TLR4 and TLR5, but not TLR3,
TLR7^9 homodimers on the cell surface (Fig. 1 C^L, upper
panels). However, after the cells were permeablized with sa-
ponin, a distinct intracellular pool for each of TLR3 and
TLR7^9 was detected (Fig. 1E, I^K, lower panels). This is
suggestive of the ability of the TM/Cyt domains to target
these four TLRs to intracellular compartments. It is not
known whether this TM/Cyt domain-directed TLR targeting
is also dependent on dimerization. Nevertheless, it was shown
that all the 10 Kv-TLR and the 10 L5-TLR chimeras were
expressed which also formed KvL5-nucleated homodimers.
3.3. TLR4/4 are the only TLR homodimers that can activate
NF-UB
Although all 10 TLR dimers were expressed in 293T cells,
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Fig. 1. Cloning and expression of the extracellular domains of integrin Kv and L5 and TLR chimeras. A: cDNA encoding the Kv and L5 extra-
cellular domains of human integrin Kv and L5 were ampli¢ed by PCR and cloned into the pcDNA3.1 vector as described in Section 2. L5 was
cloned to express both myc and His tags at the C-termini (L5-MH), whereas a stop codon was introduced between the myc and His-coding se-
quences to express Kv with only the myc tag (Kv-myc). Sequences encoding the TLR TM/Cyt domains were cloned into the Kv-myc and L5-
MH expression vectors to replace the myc/His-coding sequences. B: Kv-myc and L5-MH were co-expressed in 293T cells. L5-MH was isolated
from the culture media using Ni-NTA-agarose and the puri¢ed proteins were detected by Western blotting (WB) using monoclonal antibodies
(mAb) against the myc (K-myc) and His (K-His) epitopes and the Kv (K-Kv) and L5 (K-L5) integrin subunits. Kv-myc and L5-MH that were de-
tected on the blots have been indicated. C^L: Histograms obtained with 293T cells transfected to express KvL5-mediated TLR1/1^TLR10/10
homodimers. Kv-TLR and L5-TLR were co-expressed in 293T cells in pairs to produce KvL5-mediated TLR homodimers and these dimers were
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els: 293T cells stained after membrane permeablization with saponin. Shaded pro¢les: 293T cells transfected with the pcDNA3.1 vector and
stained with mAb P1F6.
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NF-UB was only e¡ectively activated in 293T cells that ex-
pressed the TLR4/4 homodimer (Fig. 2A). NF-UB activation
by CD4-nucleated TLR4/4 homodimers has been previously
reported [13,16,17]. In these earlier studies, other TLR homo-
dimers, including TLR1/1, TLR2/2 and TLR6/6, were also
found inactive. Therefore, homodimerization might not be a
common or su⁄cient mechanism of NF-UB activation by the
majority of TLRs.
3.4. TLR2/1 and TLR2/6 are the only TLR heterodimers that
activate NF-UB
The lack of NF-UB activation by most TLR homodimers
prompted us to examine whether TLRs would be activated
through heterodimerization. As shown in Table 1, KvL5-
nucleated TLR2/1 and TLR2/6 heterodimers were able to ac-
tivate NF-UB e¡ectively, whether Kv-TLR2 or L5-TLR2 was
used in TLR2 heterodimer expression. TLR2 heterodimers
with other TLRs were inactive (Table 1). Therefore, TLR2
activation relies on its dimerization with TLR1 or TLR6.
No other TLRs could produce heterodimers that were able
to activate NF-UB, implying that heterodimerization between
these known TLRs might also not be su⁄cient to activate
most of these TLRs.
3.5. TLR4 monomers and homodimers di¡erentially activate
NF-UB
As shown in Table 1, Kv-TLR4 or L5-TLR4 was able to
activate NF-UB in the presence of any Kv-TLR. In fact, L5-
TLR4 or Kv-TLR4 alone was also potent in NF-UB activation
(Fig. 2B). To rule out the possible experimental artifact that
Kv-TLR4 and L5-TLR4 dimerize with endogenous integrins
which clustered the TLR4 chimeras at cell-matrix focal adhe-
sion sites and led to TLR4 activation, the TLR4 TM/Cyt
domain was expressed as a chimera with the green £uores-
cence protein (GFP^TLR4). As shown in Fig. 2C, GFP-
TLR4 was as potent as the other TLR4 chimeras in NF-UB
activation. Therefore, it is clear that TLR4 monomers can
activate NF-UB. However, TLR4/4 was more potent than
TLR4 monomers in NF-UB activation (Fig. 2C).
3.6. MyD88 in NF-UB activation by TLR2/1, TLR2/6, TLR4
and TLR4/4
MyD88 is a critical adaptor protein for TLR-mediated NF-
UB activation [3^8]. However, LPS has also been reported to
activate NF-UB through a TLR-4-dependent but MyD88-in-
dependent signaling pathway [21]. We therefore examined
whether dominant negative MyD88(152^292) could inhibit
NF-UB activation by these KvL5-mediated TLR4 and TLR2
monomers/dimers. As shown in Fig. 2C, NF-UB activation by
TLR2/1 and TLR2/6 was completely blocked by MyD88(152^
292). NF-UB activation by the TLR4 monomers was also
completely inhibited (Fig. 2C). MyD88 inhibited NF-UB acti-
vation by TLR4 monomers and TLR4/4 homodimers in a
dose-dependent manner (Fig. 2D). However, residual NF-UB
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Fig. 2. NF-UB activation by TLR monomers and KvL5-mediated
TLR dimers. A: Kv-TLR and L5-TLR were co-expressed in 293T
cells as in Fig. 1C and NF-UB activation by these TLR monomers
and homodimers was determined using a luciferase assay. ‘1/1’ rep-
resents the co-expression of Kv-TLR1 and L5-TLR1. All plasmids
were used at 250 ng/well. B: 293T cells were either co-transfected
with pKvTLR4 and pL5TLR4 each at 150 ng/well (TLR4/4) or sin-
gly transfected with pKvTLR4, pL5TLR4 or pGFP-TLR4 at 300
ng/well and NF-UB activation was similarly determined using the lu-
ciferase assay. C: NF-UB activation by TLR2 and TLR4 dimers
and inhibition by dominant negative MyD88. 293T cells were trans-
fected as in A except that each TLR plasmid was used at 150 ng/
well. The cells were co-transfected with the pMyD88DN plasmid
(open bars) and, as controls, the pcDNA3.1 vector (solid bars) at
400 ng/well. The p5UNF-UB-luc and pRL-CMV luciferase reporter
plasmids were co-transfected in all experiments at the same dosage
as the TLR expression vectors. After 48 h, the activity of NF-UB-di-
rected ¢re£y luciferase was determined and normalized to the CMV-
directed Renilla luciferase activity and expressed as folds of NF-UB
activities derived from 293T cells that were transfected with the
pcDNA3.1 vector. All results are representative of at least three
similar experiments and are presented as meansUS.D. D: 293T cells
were transfected as in C except that the pMyD88DN [MyD88(152^
292)] plasmid (open bars) or, as controls, the pcDNA3.1 vector (sol-
id bars) was used at di¡erent dosages (0 ng, 80 ng, 200 ng and 400
ng).
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activation by TLR4 homodimers was consistently observed in
the presence of MyD88(152^292). This suggests that the
TLR4 homodimer, but not the TLR4 monomer, is able to
activate NF-UB through an additional, MyD88-independent
signaling pathway.
4. Discussion
The use of integrin KvL5 to nucleate TLR dimerization
enabled us to examine all possible TLR dimers in the activa-
tion of NF-UB. Our results are consistent with previous re-
ports that NF-UB can be activated by TLR2 and TLR4
dimers. No additional TLR dimers have been identi¢ed in
this study that also activate NF-UB. This implies that dimer-
ization between these known TLRs might not be su⁄cient to
activate NF-UB, although it cannot be directly tested whether
TLR dimers thus expressed adopt conformations expected
from wild type TLRs. Nevertheless, this strategy of TLR
dimer expression also led to the realization that TLR4 mono-
mers could also e¡ectively activate NF-UB. It is not clear how
TLR4 monomers activate NF-UB. However, comparing TLR
cytoplasmic sequences with that of the MyD88 TIR domain
clearly indicated that the latter was most closely related to
the TLR4 cytoplasmic domain (Fig. 3). Over-expression of
MyD88 can activate NF-UB and over-expression of wild
type TLR4 has also been shown to activate its signaling
[22]. It is possible that the TIR domains in MyD88 and
TLR4 represent a more recent duplication with both being
able to activate signaling upon elevated expression.
It was also observed in this study that NF-UB activation by
the TLR4 monomer was completely inhibited by MyD88(152^
292). In contrast, NF-UB activation displayed by TLR4 ho-
modimers was not completely inhibited. Two possible mech-
anisms are emerging that may explain this residual, MyD88-
independent NF-UB activation by TLR4 homodimers. In the
absence of MyD88, TLR4 may activate NF-UB through
the recently identi¢ed MyD88-adaptor-like (Mal) protein
[22]. However, Mal-mediated NF-UB could be inhibited by
MyD88(152^292) [22], whereas the residual NF-UB activation
by TLR4 homodimers observed in this study was not blocked
by MyD88(152^292; Fig. 2C). The other possible mechanism
that is potentially responsible for this residual, MyD88-inde-
pendent NF-UB activation by TLR4 homodimers, may in-
volve the activation of interferon-regulatory factor 3 [23].
Based on the above results, it may be proposed that TLR4
activates NF-UB following two distinct mechanisms. When
TLR4 is expressed at low levels, it may only be activated by
PAMP agonists through homodimerization which presumably
activates NF-UB through both MyD88-dependent and -inde-
pendent signaling pathways [21]. When TLR4 is persistently
expressed at high levels, such as in atherosclerosis and in£am-
matory bowel diseases [24,25], it probably activates NF-UB in
a manner independent of obvious pathogen challenges which
is characteristic of chronic in£ammation. Over-expression of
wild type TLR4 has indeed been found to activate NF-UB in
the absence of speci¢c PAMP agonist [22]. Therefore, individ-
uals who tend to exhibit enhanced or persistent TLR4 expres-
sion may be more susceptible to chronic in£ammatory con-
ditions.
It was clear from this study that homodimers of TLR3 and
TLR7^9 were only detected intracellularly, whereas the other
TLRs were detected on the cell surface, and this appears to be
determined by the cytoplasmic domains of TLRs. Interest-
ingly, comparison between cytoplasmic domains of all 10 hu-
man TLRs clearly grouped TLR7^9 as a distinct subfamily
and TLR1, TLR6 and TLR10 as another (Fig. 3). It is not
known whether cytoplasmic domain-mediated subcellular
TLR targeting is also regulated through monomer^dimer
transition. However, this set of expression constructs would
allow further study of the mechanism by which subcellular
targeting of TLRs is regulated.
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